<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56985">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842633</url>
  </required_header>
  <id_info>
    <org_study_id>RH01649</org_study_id>
    <nct_id>NCT01842633</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache</brief_title>
  <official_title>A Study to Assess Efficacy Over Placebo and Speed of Onset of Pain Relief of New Paracetamol and Caffeine Tablets as Compared to Ibuprofen in Episodic Tension Type Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multi-center study is to assess the efficacy of headache relief of new
      paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type
      headache (ETTH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sum of pain intensity difference (SPID) of experimental formulation vs placebo</measure>
    <time_frame>Baseline to 4 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>SPID to be calculated as the sum of headache intensity differences at 4 hours post-dose. Pain intensity at each time point will be calculated as difference of pain intensity at baseline with pain intensity at a given time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPID of other treatments</measure>
    <time_frame>Baseline, 1, 2, 3 and 4 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain intensity at each time point will be calculated as difference of pain intensity at baseline with pain intensity at a given time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to perceptible headache relief</measure>
    <time_frame>Baseline to 4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This endpoint will be assessed as time when participants achieve pain relief scores (PRS) more than or equal to 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to meaningful headache relief</measure>
    <time_frame>Baseline to 4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This endpoint will be assessed as time when subjects reported a PRS â‰¥ 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total pain relief (TOTPAR)</measure>
    <time_frame>1, 2, 3 and 4 hour post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>TOTPAR will be sum of products of PRS at each time point with time interval between any two time points being used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of TOTPAR and SPID (SPRID)</measure>
    <time_frame>1, 2, 3 and 4 hour post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the time-response curve for change in headache intensity and headache relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of Response to Treatment</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global evaluation of treatment response is to be measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral [neither poor nor good], 3-good, or 4-very good).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rescue medication</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects that took rescue medication over the total number of subjects for a given treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue medication</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median time taken by participants who will opt for rescue medication to be determined.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Headache, Tension-Type</condition>
  <arm_group>
    <arm_group_label>Paracetamol/ Caffeine Caplets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen Caplets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two ibuprofen caplets plus two placebo caplets to be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Caplets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four placebo caplets to be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol and Caffeine</intervention_name>
    <description>Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine</description>
    <arm_group_label>Paracetamol/ Caffeine Caplets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Caplets containing 200 mg of ibuprofen</description>
    <arm_group_label>Ibuprofen Caplets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo caplets</description>
    <arm_group_label>Placebo Caplets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants in good general health, and with diagnosis of ETTH with following
             conditions:

               1. number of days with the condition is historically greater than or equal to two
                  per month;

               2. severity of headaches is historically at least moderate;

               3. duration of headaches is historically more than or equal to 4 hours, if
                  untreated.

                  Exclusion Criteria:

          -  Participant with known or suspected hypersensitivity, allergy, intolerance or
             contraindication to the use of any of the study medications

          -  Participant has chronic tension type headache, psychiatric disease or a significant
             cognitive disorder, or any chronic pain disorder.

          -  Participant currently taking or has taken medications or herbal supplements within
             the three months that are likely to interfere with the validity of subject-rated
             assessments.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PAREXEL International, LLC</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>April 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Tension-Type Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
